^
9ms
EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • EGFR exon 20 insertion • KRAS G12 • EGFR exon 20 mutation
|
Lumakras (sotorasib) • Rybrevant (amivantamab-vmjw) • Exkivity (mobocertinib)
9ms
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
9ms
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
|
KRAS mutation • KEAP1 mutation • CDKN2A mutation • SMARCA4 mutation
9ms
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
Lumakras (sotorasib) • Krazati (adagrasib) • divarasib (RG6330)
9ms
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
10ms
Clinical • Late-breaking abstract
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
|
docetaxel • Lumakras (sotorasib)
11ms
Clinical • NCCN guideline
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)
11ms
Clinical • Adverse events
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Krazati (adagrasib)